A Less Intensive Combination of Paclitaxel and Carboplatin in Advanced Non-small Cell Lung Cancer Patients who Have Aged 60 Years or More and Has a Poor Performance Status.
- Author:
Young Joo MIN
1
;
Jong Joon AHN
;
Young Ju NOH
;
Hee Jeong CHA
;
Jae Hee SUH
;
Jong Pil JUNG
;
Chang Ryul PARK
;
Ae Kyung JEONG
;
Jae Hoo PARK
;
Ki Man LEE
Author Information
1. Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- Publication Type:Original Article ; Comparative Study
- Keywords:
Non-small Cell lung Cancer;
Elderly;
Paclitaxel;
Carboplatin
- MeSH:
Aged;
Aged, 80 and over;
Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use;
Carboplatin/administration & dosage/adverse effects;
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology;
Dose-Response Relationship, Drug;
Drug Administration Schedule;
Female;
Follow-Up Studies;
Humans;
Lung Neoplasms/*drug therapy/pathology;
Male;
Middle Aged;
Neoplasm Staging;
Paclitaxel/administration & dosage/adverse effects;
Sickness Impact Profile;
Survival Analysis;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2004;19(2):109-113
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The aim of this study was to evaluate the response, survival, and toxicities of a less intensive combination of paclitaxel and carboplatin, which is used in advanced non-small cell lung cancer (NSCLC) patients older than 60 years of age including those with a poor performance status. METHODS: Thirty patients received 135 mg/m2 of paclitaxel on day 1, and carboplatin was administered to the patients on day 1 every 4 weeks over an area under the concentration-time curve of 6. RESULTS: The response rate was 40%, the median overall survival was 9.1 months (95% CI, 4.2 to 14 months), and the 1 year survival rate was 31%. The median progression-free survival was 7.7 months (95% CI, 3.1 to 12.2 months). In addition, the toxicities were generally mild and reversible. CONCLUSION: This study demonstrates that a less intensive combination of paclitaxel/carboplatin is active and well tolerated in advanced NSCLC patients who are older than 60 years including those with a poor PS 3~4.
